Acquired salivary dysfunction. Drugs and radiation

Area of Science:

• Pharmacology and Radiation Oncology
• Salivary Gland Physiology
• Oral Medicine

Background:

• Xerostomia (oral dryness) is a common symptom of drug side effects, but often doesn't correlate with objective reductions in salivary output.
• Over 500 drugs can cause xerostomia, yet few substantially reduce salivary output; mechanisms for this discrepancy are unclear.
• Radiation therapy for head and neck cancers causes permanent salivary gland damage, affecting thousands annually.

Purpose of the Study:

• To differentiate between subjective xerostomia and objective salivary hypofunction caused by drugs.
• To review the mechanisms and permanent effects of radiation on salivary glands.
• To explore potential therapeutic interventions for radiation-induced salivary dysfunction.

Main Methods:

• Literature review of drug-induced xerostomia and salivary hypofunction.
• Analysis of studies on radiation effects on salivary glands in humans and animal models.
• Examination of preliminary clinical trial data for pilocarpine HCl efficacy.

Main Results:

• Most drugs causing xerostomia do not significantly impair salivary output; anticholinergic drugs are primary culprits for true hypofunction.
• Radiation doses exceeding 50 Gy cause permanent salivary gland damage, with mechanisms including cell death and DNA damage.
• Surviving salivary epithelial cells may retain normal function, and pilocarpine HCl shows potential in reducing radiation-induced hypofunction.

Conclusions:

• Distinguishing xerostomia from salivary hypofunction is critical for accurate diagnosis and management.
• Radiation-induced salivary damage is a significant clinical issue requiring improved preventative and therapeutic strategies.
• Further research and clinical trials are needed to develop effective treatments for radiation-induced salivary dysfunction.